Navigation Links
Echo Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Provides Business Update

PHILADELPHIA, Aug. 14, 2014 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced its financial results for the quarter ended June 30, 2014 and provided a business update.  Echo's Quarterly Report on Form 10-Q, as filed with the SEC, is available by visiting the Investors section of Echo's website at

Echo also announced today that it has taken steps to substantially reduce operating costs and preserve cash while further focusing its development efforts and resources on implementing key product performance enhancements to its Symphony CGM System. The Company has implemented significant cost reductions across all aspects of its operations in both external spend and workforce, including reductions in general and administrative expenditures, manufacturing, clinical and product development expenditures. At the same time, the Company is exploring a variety of funding alternatives which it believes, together with the cost reduction initiatives, is necessary to permit the Company to ultimately achieve its clinical trial and regulatory approval objectives. In the absence of a financing or strategic transaction, Echo's ability to achieve its previously stated product development timelines will be negatively impacted by the Company's effort to preserve cash and reduce expenses.

Cost reduction measures that were successfully implemented in September 2013 resulted in a 36% decrease in second quarter of 2014 operating expenses compared to the second quarter of 2013. The Company anticipates an additional meaningful decrease in expenses as a result of the most recent cost reduction efforts. As a result of these new initiatives, that include a 35% employee reduction, the monthly burn rate is projected to decrease by 40%-50% as compared to the average monthly burn rate experienced during the first six months of 2014.

"Our management team and Board of Directors believe more than ever in the viability of Symphony and in the positive product development progress made in the past few months; however, it is in the best interests of Echo and its shareholders to take immediate and significant action to adjust our business and operating structure in order to achieve cost savings, preserve cash and deploy capital more efficiently as we continue to make progress toward commercialization. Our focus continues to be prudent with our spending while implementing and testing the key product enhancements for the next generation Symphony CGM System," said Kimberly A. Burke, Echo's Interim CEO, General Counsel and Chief Compliance Officer. "We remain excited about the potential for Symphony as an important tool to improve glycemic control in the critical care setting and we believe that additional market segment and partnership opportunities exist for various demographics. Our SkinPrep technology also offers multi-product opportunities for use as a drug delivery device or in combination with other biosensors to monitor additional analytes."

Other Recent Corporate Updates:

  • In June 2014, Echo's clinical study of Symphony was presented during poster sessions at the 74th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California.
  • Stockholders elected Shepard M. Goldberg to the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on June 19, 2014.
  • Kimberly A. Burke was appointed as Interim Chief Executive Officer (CEO) of Echo effective July 1, 2014. The Board continues to work with a retained executive search firm to hire a well-qualified permanent CEO.
  • Charles T. Bernhardt was appointed by the Echo Board of Directors to serve as Interim Chief Financial Officer (CFO) on July 16, 2014.
  • Second Quarter 2014 Financial ResultsEcho's net loss for the second quarter of 2014 was $3.8 million, or ($0.31) per share, compared to $3.3 million, or ($0.51) per share, for the second quarter of 2013.  Operating loss for the second quarter of 2014 was $3.9 million compared to $6.1 million for the second quarter of 2013.  Research and development expenses were $1.7 million for the second quarter of 2014 compared to $4.0 million in the prior year.  The decrease in research and development expenses is primarily related to decreased development and clinical expenses.  General and administrative expenses were $2.2 million for the second quarter of 2014 versus $2.1 million in the prior year.  A decrease in general and administrative expenses was offset by unanticipated expenses that included costs associated with the proxy contest and annual shareholder meeting and legal expenses.  Echo reported a cash balance of approximately $4.1 million as of June 30, 2014.About Echo TherapeuticsEcho Therapeutics is developing the Symphony CGM System as a non-invasive, wireless continuous glucose monitoring system for use initially in the critical care setting. A significant longer-term opportunity may also exist for Symphony to be used in the hospital beyond the critical care setting, as well as in patients with diabetes in the outpatient setting. Echo has also developed its needle-free skin preparation device as a platform technology to allow for enhanced skin permeation that enables extraction of analytes, such as glucose, and enhanced delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking StatementsThe statements in this press release that are not historical facts, including the statements about future decreases in expense, corporate objectives, a European product launch and initiation of the FDA pivotal trial, may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's clinical studies, the safety and efficacy of Echo's Symphony CGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony CGM System, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell the Symphony CGM System, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony CGM System. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2013, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104Connect With Us:
    - Visit our website at 
    - Follow us on Twitter at 
    - Join us on Facebook at  Echo Therapeutics, IncCondensed Consolidated Balance Sheets(Unaudited)  June 30,2014December 31,2013ASSETSCurrent Assets:Cash and cash equivalents

    Other current assets

    1,228,9911,319,713Total current assets

    5,334,9459,375,098Net property and equipment (including assets under capitalized leases)

    1,329,5391,495,807Other Assets:Intangible assets, net of accumulated amortization

    9,625,0009,625,000Deferred financing costs, net of current portion

    2,097,3222,581,324Restricted cash and other assets

    11,49012,066Total other assets

    11,733,81212,218,390Total assets

    LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    Current portion of deferred revenue from licensing agreements

    76,42876,428Derivative warrant liability

    586,1551,119,155Accrued expenses and other liabilities

    884,2011,412,468Total current liabilities

    2,579,1443,644,371Deferred revenue from licensing arrangements, net of current portion

    38,21476,428Total liabilities

    2,617,3583,720,799Commitments and contingenciesStockholders' Equity:Convertible preferred stock, Series C, D & E

    27,49627,496Common stock

    126,654117,764Additional paid-in capital

    135,133,217132,192,648Accumulated deficit

    (119,506,429)(112,969,412)Total stockholders' equity

    15,780,93819,368,496Total liabilities and stockholders' equity


     Condensed Consolidated Statements of Operations(Unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2014201320142013Licensing revenue

    $ 19,107$ 22,557$ 38,214$ 45,114Total revenues

    19,10722,55738,21445,114Operating Expenses:Research and development

    1,747,2544,019,1493,148,1627,238,872Selling, general and administrative

    2,187,3352,098,3473,475,2354,397,794Total operating expenses

    3,934,5896,117,4966,623,39711,636,666Loss from operations

    (3,915,482)(6,094,939)(6,585,183)(11,591,552)Other Income (expense):Interest income (expense), net

    (242,994)(241,458)(486,334)(3,414,156)Gain on disposals of assets

    1500-1500-Gain on revaluation of derivative warrant liability

    393,0002,995,000533,0004,675,986Other income (expense), net

    151,5062,753,54248,1661,261,830Net loss

    $ (3,763,976)$ (3,341,397)$ (6,537,017)$ (10,329,722)Net loss per common share, basic and diluted

    $ (0.31)$ (0.51)$ (0.55)$ (1.73)Basic and diluted weighted average common shares outstanding

    12,070,5486,594,53011,965,3065,987,376(Reflects 1-for-10 reverse stock split effective June 7, 2013)


    SOURCE Echo Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
    2. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
    3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    4. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
    5. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
    6. Caliber and ImmunGene Launch Valor Biotherapeutics, a Joint Venture to Develop Antibody-Interferon Fusion Therapeutics to Treat Cancers
    7. Cadence Pharmaceuticals Announces Termination of Option Agreement to Acquire Incline Therapeutics, Inc.
    8. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
    9. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
    10. Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors
    11. ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
    Post Your Comments:
    (Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
    (Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
    (Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
    (Date:11/25/2015)... ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Smart and Beddit Classic sleep tracking systems. The new app features a more intuitive ... see and understand how well you slept. The SleepScore is created by a proprietary ...
    (Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
    Breaking Medicine News(10 mins):